Obtaining Human Microglia from Adult Human Brain Tissue
August 30th, 2020
7.3K views
This protocol is an efficient, cost effective and robust method of isolating primary microglia from live, adult, human brain tissue. Isolated primary human microglia can serve as a tool for studying cellular processes in homeostasis and disease.
Overview
This protocol outlines a method for efficiently isolating primary microglia from live adult human brain tissue collected during surgery. The protocol emphasizes cost-effectiveness and robustness, allowing for further study of cellular processes in both homeostasis and disease contexts.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Microglial Research
Background
- Microglia are the resident immune cells of the central nervous system.
- They play crucial roles in maintaining homeostasis and responding to injury.
- Isolation of primary human microglia is essential for studying their functions.
Purpose of Study
- To provide a robust method for isolating primary human microglia.
- To reduce the number of steps in existing protocols to minimize cell loss.
- To facilitate the use of human microglia in experimental settings.
Methods Used
- The method involves cell culture techniques using live adult human brain tissues.
- Tissues are collected, diced, and treated with trypsin EDTA to isolate cells.
- The protocol includes critical steps like maintaining tissue temperature to prevent cell death.
- Cells are cultured in a suitable medium and characterized using immunocytochemistry.
Main Results
- The protocol effectively isolates primary human microglia with a high yield.
- About 80% of cultured cells were identified as microglia, confirming isolation success.
- Cell characterization using immunocytochemistry revealed clear distinctions between microglia and other cell types.
Conclusions
- This study demonstrates an efficient method for isolating microglia, enabling further research.
- The method's robustness enhances its applicability for downstream experiments in neuroscience.
- Understanding the role of microglia in health and disease could improve therapeutic strategies.
Frequently Asked Questions
What are the advantages of this isolation method?
This method is cost-effective and reduces cell loss by minimizing the number of procedural steps compared to traditional protocols.
How is the brain tissue handled during the process?
Brain tissue is collected in ice cold PBS and processed immediately to prevent cell death, ensuring efficient isolation.
What types of cells are obtained from this protocol?
The protocol primarily yields microglia, with a purity of approximately 80% as confirmed by immunocytochemistry.
How long does the entire isolation procedure take?
The complete microglia isolation procedure can be accomplished in about one and a half hours.
Can this protocol be adapted for other cell types?
While the protocol is specifically designed for microglia, similar techniques may be adapted for other primary cell types with modifications.
What are the key limitations of this method?
One limitation includes the need for fresh brain tissue, which may not always be readily available.
How can the isolated microglia be used in further experiments?
Isolated microglia can be used to study their function in various experimental setups, including disease models and neuroinflammatory responses.
Executive Industry Relevance
Isolation of primary human microglia from adult brain tissue enables mechanistic de-risking in neuroimmunology target validation by providing a disease-relevant system that mirrors in vivo immune phenotypes. This supports predictive confidence in preclinical models for CNS disorders, including autoimmune and neurodegenerative conditions, by facilitating direct study of microglial phenotypes and cell-cell interactions. The method enhances translational continuity from discovery to preclinical research, reducing biological risk in therapeutic hypothesis testing.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of microglial phenotypes in disease contexts to clarify immune-mediated pathogenic mechanisms.
- Operational Value: Provides a robust, cost-effective source of primary human microglia for functional target de-risking.
- Predictive Value: Supports assessment of target engagement and immunomodulatory effects in a human-relevant system.
Screening & Assay Development
- Scientific Value: Generates validated microglial cultures suitable for assay standardization and reproducibility testing.
- Operational Value: Yields ~80% pure microglia as confirmed by immunocytochemistry, enabling reliable compound screening.
- Scalability: Supports preparation of validated biological systems for downstream workflows in drug discovery.
Translational & Preclinical Research
- Translational Relevance: Uses adult human microglia, which exhibit distinct properties vs. fetal or rodent models, improving disease relevance.
- Mechanistic De-risking: Allows characterization of microglial interactions with neurons, astrocytes, and oligodendrocytes in CNS co-culture systems.
- Preclinical Continuity: Supports risk-adjusted advancement decisions by modeling human neuroimmune responses in vitro.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through preclinical research, enabling isolation of primary microglia for use in functional assays and mechanistic studies prior to lead optimization.
- Discovery Biology: Supports hypothesis testing of microglial roles in neuroinflammation and immune dysregulation in disease models.
- Screening: Delivers standardized, quantitative microglial cultures for assessing compound effects on immune activation or phagocytosis.
- Analytics: Enables immunocytochemical readouts and quantification of microglial purity and activation states for comparative condition analysis.
- Translational Research: Connects to preclinical validation via human-relevant microglial phenotypes that inform biomarker alignment and therapeutic response prediction.
- Enterprise Reuse: Establishes a reusable isolation capability for consistent microglial sourcing across projects and therapeutic areas.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through human-relevant microglial models that reduce mechanistic ambiguity.
- Operational Value: Standardization and reproducibility via a robust protocol minimizing cell loss and technical variability.
- Strategic Value: Improved go/no-go decisions by de-risking immunomodulatory targets early in the discovery pipeline.
- Portfolio Impact: Risk-adjusted prioritization of CNS therapeutics based on human microglial response data.
Implementation Considerations
- Requires expertise in primary cell culture and sterile tissue handling from surgical specimens.
- Dependent on access to fresh adult human brain tissue collected under aseptic conditions.
- Necessitates temperature-controlled processing (ice-cold and 37°C steps) to prevent cell death during isolation.
- Requires standardized culture media formulation including L929 supernatant for microglial maintenance.
- Limited by tissue availability and viability constraints, which may affect scalability across sites.
Biopharma FAQs
Why is microglial purity critical for target validation in neuroimmunology?
The protocol yields approximately 80% pure microglia as confirmed by immunocytochemistry, enabling reliable assessment of target-specific immune responses without confounding signals from astrocytes or other CNS cells. High purity supports mechanistic de-risking by isolating microglial contributions to pathogenic pathways in disease models.
How does tissue temperature control during isolation impact experimental reproducibility?
Maintaining tissue in ice-cold PBS followed by warm aCSF and PBS steps prevents cell death and preserves microglial viability and functionality. This temperature-sensitive protocol step is critical for obtaining consistent yields and functional microglia across replicates, directly affecting assay reliability.
What quantitative outputs enable comparison of microglial activation states across experimental conditions?
Immunocytochemistry using RCA lectin staining allows quantification of microglial density and morphology, with the protocol achieving ~80% microglial purity in culture. These measurements support side-by-side comparison of activation states, phagocytic activity, or phenotypic shifts in response to immunomodulatory compounds.
Why are replication requirements essential for cross-functional collaboration in microglial research?
The protocol’s robustness and reduced cell loss enable reproducible isolation of primary microglia from multiple human tissue samples, supporting consistent data generation across teams. Reproducible microglial sourcing ensures alignment between discovery, assay development, and preclinical groups studying neuroimmune targets.
What statistical analysis capabilities are required before implementing this isolation method in a discovery pipeline?
Implementation requires basic quantitative analysis of microglial yield and purity via immunocytochemistry image quantification, as demonstrated in the protocol’s Section C results. Teams must be able to quantify microglial percentage and assess variability across preparations to establish acceptance criteria for downstream use.
